Bioprocess development depends on reliable scale-down models to generate decision-ready data quickly. In this white paper, we present a side-by-side comparison of two 250 mL bioreactor platforms running a fed-batch CHO process, evaluating their impact on cell growth, metabolism, and product yield. While both systems demonstrate comparable performance across key process metrics, the Stratyx™ platform consistently delivers higher cell viability and increased IgG titer without compromising product quality. These findings highlight how advanced bioreactor design and control can improve process outcomes, reduce risk, and accelerate the path to manufacturing. Download the white paper below.